Revvity (NYSE:RVTY) Releases Earnings Results, Beats Estimates By $0.15 EPS

Revvity (NYSE:RVTY) released its quarterly earnings data on Monday. The company reported $1.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.55 by $0.15, Briefing.com reports. Revvity had a return on equity of 7.52% and a net margin of 8.44%.During the same quarter last year, the company posted $1.42 earnings per share. The firm’s revenue was up 5.9% on a year-over-year basis. Revvity updated its FY 2026 guidance to 5.350-5.450 EPS.

Here are the key takeaways from Revvity’s conference call:

• Revvity closed Q4 with stronger-than-expected results—Q4 organic growth of 4% and adjusted EPS of $1.70, while full-year adjusted EPS of $5.06 topped guidance; management repurchased over $800M of shares in 2025 (>$1.5B since 2023).
• 2026 initial guidance is conservative — management forecasted 2%–3% organic growth, total revenue of $2.96B–$2.99B, 28% adjusted operating margin, and adjusted EPS of $5.35–$5.45, but said upside is possible if end markets improve.
• Diagnostics drove Q4 strength (diagnostics organic +7%), led by reproductive health and immunodiagnostics, while life-sciences reagents were flat and instruments showed a meaningful sequential recovery, signaling improving demand trends.
• Strategic software push — Revvity launched the Signals Synthetica AI platform, closed the ACD/Labs acquisition (expected to add ?$20M revenue / ~75bps), and announced a collaboration with Lilly to accelerate adoption of its Signals software.
• Ongoing headwinds — DRG-related volume pressures in China are expected to persist through about the end of Q2, and Q1 adjusted operating margins are guided down to about 23% due to an extra operating week, tariffs, and cost programs not yet fully implemented.

Revvity Price Performance

Shares of RVTY stock opened at $104.54 on Monday. Revvity has a 52-week low of $81.36 and a 52-week high of $126.57. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.44 and a current ratio of 1.75. The stock has a market cap of $11.85 billion, a PE ratio of 52.09, a PEG ratio of 3.32 and a beta of 1.06. The firm’s 50 day moving average price is $103.96 and its two-hundred day moving average price is $95.44.

Revvity Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 8th. Stockholders of record on Friday, April 17th will be given a dividend of $0.07 per share. The ex-dividend date is Friday, April 17th. This represents a $0.28 annualized dividend and a dividend yield of 0.3%. Revvity’s payout ratio is currently 14.07%.

Institutional Investors Weigh In On Revvity

Several large investors have recently made changes to their positions in RVTY. Mackenzie Financial Corp raised its stake in shares of Revvity by 1.7% during the third quarter. Mackenzie Financial Corp now owns 8,955 shares of the company’s stock valued at $785,000 after acquiring an additional 154 shares during the last quarter. EverSource Wealth Advisors LLC lifted its stake in shares of Revvity by 25.9% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 900 shares of the company’s stock valued at $87,000 after purchasing an additional 185 shares during the period. Schroder Investment Management Group raised its position in shares of Revvity by 5.0% during the third quarter. Schroder Investment Management Group now owns 4,751 shares of the company’s stock worth $416,000 after purchasing an additional 225 shares during the period. American Century Companies Inc. lifted its stake in Revvity by 4.3% during the 2nd quarter. American Century Companies Inc. now owns 5,529 shares of the company’s stock valued at $535,000 after acquiring an additional 227 shares in the last quarter. Finally, CYBER HORNET ETFs LLC purchased a new position in Revvity during the 2nd quarter worth $32,000. Institutional investors own 86.65% of the company’s stock.

Revvity declared that its Board of Directors has authorized a stock buyback plan on Monday, October 27th that allows the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization allows the company to purchase up to 8.7% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s board of directors believes its stock is undervalued.

Analysts Set New Price Targets

A number of brokerages recently weighed in on RVTY. Weiss Ratings restated a “sell (d)” rating on shares of Revvity in a report on Monday, December 29th. Robert W. Baird boosted their price target on Revvity from $122.00 to $123.00 and gave the company an “outperform” rating in a research note on Tuesday, October 28th. The Goldman Sachs Group assumed coverage on Revvity in a research note on Tuesday, December 9th. They issued a “neutral” rating and a $105.00 price objective on the stock. Evercore ISI reiterated an “outperform” rating on shares of Revvity in a report on Monday, January 5th. Finally, Wells Fargo & Company lifted their price objective on Revvity from $102.00 to $107.00 and gave the stock an “equal weight” rating in a report on Monday, December 15th. Six research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Revvity presently has an average rating of “Hold” and an average price target of $113.91.

About Revvity

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.